Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma
Omid Hamid, Karl D. Lewis, Amy Weise, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 24, pp. 2928-2938
Open Access | Times Cited: 19

Showing 19 citing articles:

Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment
Dimitrios C. Ziogas, Charalampos Theocharopoulos, Panagiotis-Petros Lialios, et al.
Cancers (2023) Vol. 15, Iss. 10, pp. 2718-2718
Open Access | Times Cited: 46
Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib/II trial
Gang Chen, Dong-Chen Sun, Yi Ba, et al.
Journal of Hematology & Oncology (2025) Vol. 18, Iss. 1
Open Access | Times Cited: 2
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024
Claus Garbe, Teresa Amaral, Ketty Peris, et al.
European Journal of Cancer (2024) Vol. 215, pp. 115153-115153
Open Access | Times Cited: 11
LAG‐3 : recent developments in combinational therapies in cancer
Aude Chavanton, Flavie Mialhe, Jimena Abrey, et al.
Cancer Science (2024) Vol. 115, Iss. 8, pp. 2494-2505
Open Access | Times Cited: 8
Deciphering T-cell exhaustion in the tumor microenvironment: paving the way for innovative solid tumor therapies
Reshmi S. Nair, Veena Somasundaram, Anshu Kuriakose, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Advances in LAG3 cancer immunotherapeutics
Kieran Adam, Samuel C. Butler, Creg J. Workman, et al.
Trends in cancer (2024)
Closed Access | Times Cited: 3
Mechanisms of Resistance to Anti-PD-1 Immunotherapy in Melanoma and Strategies to Overcome It
M.K. Zielińska, Magdalena Ciążyńska, Dorota Sulejczak, et al.
Biomolecules (2025) Vol. 15, Iss. 2, pp. 269-269
Open Access
The tetravalent, bispecific properties of FS118, an anti-LAG-3/PD-L1 antibody, mediate LAG-3 shedding from CD4+ and CD8+ tumor-infiltrating lymphocytes
Claire S. Reader, Wenjia Liao, Beatrice J. Potter-Landua, et al.
Anti-Cancer Drugs (2025)
Closed Access
Integrated AI and machine learning pipeline identifies novel WEE1 kinase inhibitors for targeted cancer therapy
Jaikanth Chandrasekaran, D. Gopal, Lokesh Vishwa Sureshkumar, et al.
Molecular Diversity (2025)
Closed Access
Emerging new immune checkpoint inhibitors in solid tumor immunotherapy
Amirhoushang Poorkhani, Mahboubeh Tajaldini, Farahnazsadat Ahmadi, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
First-in-human phase I study of EMB-02, a bispecific antibody targeting PD-1 and LAG-3 in patients with advanced solid tumors
Daphne Day, Vinod Ganju, Ki Y. Chung, et al.
British Journal of Cancer (2025)
Open Access
Clinical Applications of the Molecular Landscape of Melanoma: Integration of Research into Diagnostic and Therapeutic Strategies
Imre Szabó, Gabriella Emri, Andrea Ladányi, et al.
Cancers (2025) Vol. 17, Iss. 9, pp. 1422-1422
Open Access
TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives
Zhuohong Yan, Chunmao Wang, Jinghong Wu, et al.
Molecular Biomedicine (2025) Vol. 6, Iss. 1
Open Access
One Step Ahead: Preventing Tumor Adaptation to Immune Therapy
Erica Braverman, Giuliana P. Mognol, Andy J. Minn, et al.
American Society of Clinical Oncology Educational Book (2025) Vol. 45, Iss. 3
Closed Access
The emerging role of lymphocyte‐activation gene 3 targeting in the treatment of solid malignancies
Vinay K. Giri, David H. McDermott, Jacob P. Zaemes
Cancer (2025) Vol. 131, Iss. 10
Closed Access
Deciphering LAG-3: unveiling molecular mechanisms and clinical advancements
Alejandra Martínez‐Pérez, Rocío Granda‐Díaz, Candelaria Aguilar-García, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 1
Immune Checkpoint Inhibitors in Cancer Immunotherapy
Fathima Hasnain Nadeem Hussain, Afsheen Raza
Advances in medical diagnosis, treatment, and care (AMDTC) book series (2024), pp. 123-156
Closed Access
Quoi de neuf en oncodermatologie ?
Elisa Funck‐Brentano
Annales de Dermatologie et de Vénéréologie - FMC (2024) Vol. 4, Iss. 8, pp. 8S36-8S44
Closed Access
LAG3 immune inhibitors: a novel strategy for melanoma treatment
Renzheng Wu, Mingtang Zeng, Yuchen Zhang, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
Page 1

Scroll to top